TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35222899
Drug: Conventional conservative
Normalized name: Conserved dopamine neurotrophic factor
DrugBank: HER-902 (DB17948)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional conservative treatment (control group)
Study: 32822614
Drug: Sildenafil (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil (20 mg three times daily) added to pirfenidone (801 mg three times daily)
Study: 32822614
Drug: Placebo added
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo added to pirfenidone (801 mg three times daily)
Study: 35799106
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Group C) - PCA drugs only in the constant flow chamber with normal saline in the adjustable flow chamber
Study: 32951121
Drug: Passiflora incarnata
Normalized name: Passiflora incarnata
Approvals — FDA: no, EMA: no, PMDA: no
Description: Passiflora incarnata (500 mg)
Study: 32951121
Drug: Erythrina mulungu
Normalized name: Erythrina variegata bark extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythrina mulungu (500 mg)
Study: 35428324
Drug: Baihu and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baihu and Guizhi decoction (BHGZ) plus low-dose colchicine
Study: 35428324
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus low-dose colchicine
Study: 33475705
Drug: Irinotecan monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan monotherapy
Study: 35995058
Drug: Face-to-Face (F2F)
Normalized name: FACE SHIELD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Face-to-Face (F2F) therapy
Study: 36138055
Drug: Sham therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham therapy (placebo needles)
Study: 32896504
Drug: Hormone group
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone group (3‐day, low‐dose glucocorticoid treatment plus conventional treatment; 63 patients)
Study: 32896504
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (conventional treatment only; 62 patients)
Study: 33769174
Drug: Low-dose acetylsalicylic
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose acetylsalicylic acid (ASA) 100 mg/day
Study: 36123366
Drug: Atezolizumab 840
Normalized name: atezolizumab 840 MG in 14 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atezolizumab 840 mg every 2 weeks for 5 cycles (4 weeks/cycle) plus weekly nab-paclitaxel for 3 cycles, followed by atezolizumab 1200 mg every 3 weeks for 11 cycles after surgery.
Study: 36123366
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with weekly nab-paclitaxel for 3 cycles, followed by standard of care.
Study: 37122487
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment for 8 weeks
Study: 36425922
Drug: Superficial SAP
Normalized name: Bambusa vulgaris sap extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Superficial SAP block with 30 ml 0.375% ropivacaine (group S)
Study: 36425922
Drug: Deep SAP
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deep SAP block with 30 ml 0.375% ropivacaine (group D)
Study: 32996671
Drug: Topical oral
Normalized name: aloe vera topical oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical oral vitamin D gel
Study: 32996671
Drug: Topical oral
Normalized name: aloe vera topical oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical oral vitamin D gel plus conventional treatment
Study: 32996671
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy group (vitamin D gel + conventional treatment)
Study: 33261257
Drug: Injections of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injections of corticosteroids
Study: 33261257
Drug: Injective therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injective therapy with local anaesthetics
Study: 32768713
Drug: CSSP +
Approvals — FDA: no, EMA: no, PMDA: no
Description: CSSP + dual-phase gel (CSSP + Serum)
Study: 33050947
Drug: Favipiravir 1800
Normalized name: favipiravir
DrugBank: Favipiravir (DB12466)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Favipiravir 1800 mg BD on Day 1 followed by 800 mg BD for the next 13 days
Study: 33678522
Drug: Sunitinib monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib monotherapy
Study: 35922776
Drug: Lactase (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactase (600 FCC units/mL), 5 drops mixed with breast milk or formula feed, four times a day for 4 weeks
Study: 35922776
Drug: Lactase (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactase (600 FCC units/mL)
Study: 32755100
Drug: Vitamins C
Normalized name: MULTIVITAMINS CAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamins C and E (400 IU/day of vitamin E and 1000 mg/day of vitamin C)
Study: 32755100
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (iron tablets only)
Study: 36004739
Drug: Reboxetine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reboxetine (4 mg) + Oxybutynin (5 mg)
Study: 37337241
Drug: Empirical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empirical therapy (Bismuth quadruple therapy as first-line, high-dose dual therapy as rescue)
Study: 37337241
Drug: Susceptibility-guided sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Susceptibility-guided sequential strategy (clarithromycin triple therapy for clarithromycin-sensitive strains, high-dose dual therapy for clarithromycin-resistant strains, levofloxacin quadruple regimen for levofloxacin-sensitive strains, furazolidone quadruple regimen for others)
Study: 35313959
Drug: UC-MSCs infusion
Normalized name: Astri-UC
Approvals — FDA: no, EMA: no, PMDA: no
Description: UC-MSCs infusion (3 doses of 5×10^5 cells/kg with a dosing interval of 48 hours)
Study: 33687747
Drug: Molecularly-guided therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Molecularly-guided therapy
Study: 33290610
Drug: All treatment
Normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: All treatment arms (T, L, TL, LT)
Study: 33290610
Drug: Progesterone receptor
Normalized name: Progesterone receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progesterone receptor (PR)–negative tumors
Study: 38049621
Drug: Bivalent vaccine
Normalized name: PAPILLOMAVIRUS BIVALENT VACCINE INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalent vaccine
Study: 35794660
Drug: Lisinopril/amlodipine tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril/amlodipine tablets (test and reference)
Study: 32017643
Drug: Text-message reminders
Approvals — FDA: no, EMA: no, PMDA: no
Description: Text-message reminders for second dose of influenza vaccine
Study: 35470256
Drug: Stabilisation exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stabilisation exercise group (SEG) - exercise protocol twice a week for 12 weeks
Study: 32943657
Drug: Cystoinflation (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cystoinflation (300 cc saline retro-fill)
Study: 36107462
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment in secondary prevention RCTs
Study: 32985775
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine for 3 months followed by metformin for 9 months (G→Met)
Study: 32985775
Drug: Metformin alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin alone (Met) for 12 months
Study: 33274381
Drug: Testosterone cream
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone cream (10 mg daily for 10 weeks)
Study: 33214190
Drug: Rapid-acting insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid-acting insulin (RAI)
Study: 33214190
Drug: Human regular
Normalized name: Human regular insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human regular insulin (HRI)
Study: 32965493
Drug: Early endovenous
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early endovenous ablation with compression therapy within 2 weeks of randomization (n = 224)
Study: 32965493
Drug: Deferred endovenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferred endovenous treatment with compression therapy (n = 226)
Study: 35152577
Drug: Caltrate (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caltrate (2 pills a day for 4 weeks)
Study: 34029565
Drug: Nicotine transdermal
Normalized name: NICOTINE TRANSDERMAL KIT
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine transdermal patch treatment (21 mg daily)
Study: 34029565
Drug: Placebo patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo patch use
Study: 33300578
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg lorazepam (active control)
Study: 32671846
Drug: Lialda 2
Normalized name: Lialda
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lialda 2 × 1.2 g once daily (QD)
Study: 32671846
Drug: Asacol 6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Asacol 6 × 400 mg QD
Study: 32671846
Drug: Asacol 2
Normalized name: Asacol 250 MG Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Asacol 2 × 400 mg three times daily (TID)
Study: 35648298
Drug: Weight loss
Normalized name: HERBAL WEIGHT LOSS AID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight loss treatment
Study: 32221405
Drug: Drug use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug use (especially injectable drugs)
Study: 32221405
Drug: Class-A drug
Normalized name: VARIOUS DRUG CLASSES IN ATC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Class-A drug use
Study: 33565742
Drug: Neurofacilitation (three
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neurofacilitation (three types of physical therapy: Motor Program Activating Therapy, Vojta's reflex locomotion, Functional Electric Stimulation in Posturally Corrected Position)
Study: 33565742
Drug: Neurofacilitation (irrespective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neurofacilitation (irrespective type of therapy)
Study: 36306497
Drug: Ablative therapies
Normalized name: ABL
DrugBank: Lauric acid (DB03017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ablative therapies (such as surgery or radiation)
Study: 36652155
Drug: Metastasis-directed therapy
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metastasis-directed therapy
Study: 32327014
Drug: Standardized laptop
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized laptop (L)
Study: 33184754
Drug: Cisplatin (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (80 mg/m2) on day 1 plus Gemcitabine (1000 mg/m2) on days 1 and 8 every 3 weeks
Study: 33184754
Drug: Carboplatin (AUC:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carboplatin (AUC: 6 mg/mL/min) on day 1 plus Nab-paclitaxel (75 mg/m2) on days 1, 8, and 15 every 3 weeks
Study: 32873667
Drug: Vildagliptin 50
Normalized name: vildagliptin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vildagliptin 50 mg per day
Study: 38253701
Drug: ACE inhibitors/ARBs
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitors/ARBs
Study: 35505199
Drug: SRP with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRP with combined air polishing (erythritol/chlorhexidine powder) and Nd:YAG laser (2 W, 200 mJ/pulse, 10 Hz) therapy
Study: 35524961
Drug: KBAM (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: KBAM (200 mg ketamine, 109.2 mg butorphanol, 36.4 mg azaperone, 43.6 mg medetomidine)
Study: 35524961
Drug: DEA (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: DEA (40 mg detomidine premedication, followed 20 minutes later by 3.9 to 4.4 mg etorphine and 16 to 18 mg acepromazine)
Study: 35956202
Drug: Esketamine/Propofol (esketamine:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esketamine/Propofol (esketamine: 0.2 mg/kg)
Study: 35956202
Drug: Sufentanil/Propofol (sufentanil:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil/Propofol (sufentanil: 0.2 μg/kg)
Study: 33022421
Drug: 5-aminolevulinic acid
Normalized name: 5-aminolevulinic acid
DrugBank: Aminolevulinic acid (DB00855)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-aminolevulinic acid photodynamic therapy (5ALA-PDT)
Study: 33302661
Drug: 20 mL
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL 0.375% ropivacaine
Study: 33302661
Drug: 30 mL
Normalized name: Vial M/T 30 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mL 0.375% ropivacaine
Study: 33400845
Drug: Savolitinib 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Savolitinib 600 mg
Study: 32736046
Drug: Intranasal herbal
Normalized name: Hyperici herba
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal herbal oil (containing violet oil, saffron oil, and lettuce seeds oil)
Study: 34337913
Drug: Anti-IL-6R therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anti-IL-6R therapy (Tocilizumab and Sarilumab)
Study: 34337913
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no anti-IL-6R therapy)
Study: 32463566
Drug: Atorvastatin (ATV)
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atorvastatin (ATV) in uncontrolled SLE group
Study: 32463566
Drug: Atorvastatin (ATV)
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atorvastatin (ATV) in controlled SLE group
Study: 34221381
Drug: Pioglitazone 15
Normalized name: pioglitazone 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone 15 mg
Study: 33569576
Drug: DAS181 (4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAS181 (4.5 mg/day)
Study: 32718528
Drug: Aprepitant 250
Normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aprepitant 250 mg/day orally for 15 days
Study: 33598889
Drug: Intravenous dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous dexmedetomidine (50 µg)
Study: 32139280
Drug: Ticagrelor monotherapy
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor monotherapy after 1 month of dual-antiplatelet therapy (DAPT) for 23 months
Study: 32139280
Drug: Standard DAPT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard DAPT for 12 months followed by aspirin monotherapy
Study: 34824180
Drug: Lidocaine 1.5%
Normalized name: LIDOCAINE 1.5%/EPI 1:200000 INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 1.5% with adrenaline and dexamethasone 8 mg
Study: 32681239
Drug: Antidepressant medication
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant medication use (28% of patients, n = 223)
Study: 33740496
Drug: Exercise group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise group (EG) - 12 weeks of a structured physical exercise program, consisting of two 60‐min weekly sessions including warm-up, aerobic training, resistance training, and stretching.
Study: 34715810
Drug: Surgery +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgery + intraoperative HIPEC (cisplatin 75 mg/m2 at 42°C for 90 min) and postoperative FLOT (Docetaxel 50 mg/m2; Oxaliplatin 85 mg/m2; Leucovorin 200 mg/m2; 5-FU 2600 mg/m2, q2wk)
Study: 35101369
Drug: Shexiang Tongxin
Normalized name: CAMPHOR (NATURAL) 30.53 mg / MENTHOL 40.71 mg / METHYL SALICYLATE 25.95 mg TOPICAL PLASTER [SheXiang ZhuangGu Gao]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shexiang Tongxin Dropping Pill (STDP) plus dual antiplatelet therapy (DAPT) with clopidogrel and aspirin
Study: 34224251
Drug: Deferoxamine (DFO):
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferoxamine (DFO): 100 mg/kg SC q24 h
Study: 34224251
Drug: Deferiprone (DFP):
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferiprone (DFP): oral, 75 mg/kg
Study: 34224251
Drug: Deferoxamine +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferoxamine + Phlebotomy (DFO + F): 100 mg/kg SC q24 h with phlebotomy
Study: 34224251
Drug: Deferiprone +
Normalized name: Deferiprone
DrugBank: Deferiprone (DB08826)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Deferiprone + Phlebotomy (DFP + F): oral, 75 mg/kg with phlebotomy
Study: 34784889
Drug: Ultrasound-guided paravertebral
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided paravertebral block (PVB) with 30 mL of 0.5% ropivacaine
Study: 34784889
Drug: Ultrasound-guided retrolaminar
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided retrolaminar block (RLB) with 30 mL of 0.5% ropivacaine
Study: 32029355
Drug: Eliglustat coadministered
Normalized name: Eliglustat
DrugBank: Eliglustat (DB09039)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Eliglustat coadministered with oral contraceptives
Study: 32029355
Drug: Acid-reducing agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acid-reducing agents coadministered with eliglustat
Study: 36090126
Drug: Super Floss®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Super Floss® (Oral-B)
Study: 36090126
Drug: Super Floss®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Super Floss® (Oral-B) and Waterpik® water flosser
Study: 36413252
Drug: Optimized dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimized dosing of pemetrexed (n = 37)
Study: 36413252
Drug: Standard BSA-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard BSA-based dosing (n = 44)
Study: 33820919
Drug: Artificial liver
Normalized name: LIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artificial liver support system (ALSS) treatment
Study: 34363198
Drug: GnRH antagonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH antagonist pre-treatment for 60 days
Study: 34927308
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of glatiramer acetate and interferon beta
Study: 33191846
Drug: iddEPC group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: iddEPC group (n=424) - neo-adjuvant dose-dense, dose-intensified epirubicin, paclitaxel, and cyclophosphamide
Study: 33191846
Drug: NT-proBNP measured
Approvals — FDA: no, EMA: no, PMDA: no
Description: NT-proBNP measured at 6 weeks after treatment initiation
Study: 33191846
Drug: Hemoglobin measured
Normalized name: HEMOGLOBIN
DrugBank: Hemoglobin (DB04945)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemoglobin measured at 6 weeks after treatment initiation
Study: 616117430
Drug: Copaxone (glatiramer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Copaxone (glatiramer acetate), weekly subcutaneous injections for 12 weeks
Study: 36252599
Drug: Lurbinectedin plus
Normalized name: lurbinectedin
DrugBank: Lurbinectedin (DB12674)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lurbinectedin plus doxorubicin (2.0 mg/m2 plus 40.0 mg/m2 on day 1 of 21-day cycles)
Study: 36252599
Drug: Control (topotecan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (topotecan 1.5 mg/m2 on days 1-5 of 21-day cycles; or CAV: cyclophosphamide 1000 mg/m2, doxorubicin 45.0 mg/m2, and vincristine 2.0 mg on day 1 of 21-day cycles)
Study: 33345481
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese therapy of tonifying the kidney and invigorating blood circulation (TKIB), n = 22
Study: 33345481
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (oral tamoxifen tablets and vitamin E capsules), n = 20
Study: 34160459
Drug: Food preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Food preparation program (n=11)
Study: 32485112
Drug: Platelet-Rich Plasma
Normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet-Rich Plasma (PRP) injections (4 injections, 14 days apart)
Study: 32485112
Drug: Placebo injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injections (4 injections of saline, <0.5 mL, under the skin, 14 days apart)
Study: 33245866
Drug: Intravenous ferric
Normalized name: Ferric Oxide
DrugBank: Ferric oxide (DB11576)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ferric carboxymaltose (1000 mg to 2000 mg based on bodyweight and haemoglobin concentration)
Study: 33245866
Drug: Oral iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral iron (three dried ferrous sulphate tablets of 200 mg containing 60 mg of elemental iron and 5 mg of folic acid every morning for 3 months)
Study: 34128358
Drug: Nasal carrageenan
Normalized name: Carrageenan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal carrageenan administered three times per day for 7 days
Study: 35286843
Drug: CD24Fc 480
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD24Fc 480 mg
Study: 33407631
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg of CFE
Study: 33407631
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg of CFE
Study: 32919517
Drug: Valaciclovir (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valaciclovir (8 g per day, twice daily)
Study: 32899071
Drug: Chemotherapy containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy containing bevacizumab (folinic acid, bolus/continuous fluorouracil, and irinotecan)